RT Journal Article SR Electronic T1 Implementation of a Non-Invasive Helmet Ventilation Solution for the Management of Severe COVID-19 Respiratory Disease in Nigeria: The CircumVent Project JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.08.30.22279372 DO 10.1101/2022.08.30.22279372 A1 Aima A. Ahonkhai A1 Aliyu Abdu A1 Olukemi Adekanmbi A1 Nnennaya A. Ajayi A1 Samuel Ajayi A1 Happy Akpobi A1 Ejiro Benjamin Akpochafo A1 Muktar H. Aliyu A1 Adaeze C Ayuk A1 Adedamola A. Dada A1 Oliver C. Ezechi A1 Catherine O. Falade A1 Alex Horstein A1 Idowu Olusola A1 Ifeoma Idigbe A1 Sunday Mogaj A1 Aleem A. Morenikeji A1 Baba M. Musa A1 Nnamdi I. Nwosu A1 Adenike A Odewabi A1 Igho Ofokotun A1 Gbenga Ogedegbe A1 Onome Ogueh A1 Temitope O Oyewole A1 Adeshola I. Sotannde A1 Alan B. Steinbach A1 Ifeoma I. Ulasi A1 Kingsley N. Ukwaj A1 Uchechukwu S. Unigwe A1 Olagoke A. Usman A1 Cyril Uzoke A1 Adesola Z. Musa A1 Muyiwa K. Rotimi A1 Iorhen E. Akase A1 Wasiu L. Adeyemo A1 André A. Fenton A1 Babatunde L. Salako YR 2022 UL http://medrxiv.org/content/early/2022/09/01/2022.08.30.22279372.abstract AB Affordable novel strategies are needed to treat COVID-19 cases complicated by respiratory compromise in resource limited settings. We report a mixed-methods pre-post assessment of 1) the useability of CPAP/O2 helmet non-invasive ventilation (NIV) to treat COVID-19, at ∼ 1% the cost of mechanical ventilation; 2) the effectiveness of a train-the-trainer practice facilitation intervention; and 3) whether use of CPAP/O2 helmet NIV was associated with increased COVID-19 infection among healthcare workers. At baseline, eight COVID-19 treatment centers in Nigeria (CircumVent network) received CPAP/O2 helmet systems, and were instructed on its use. After five months, clinicians within the CircumVent netwok participated in a 2-day train-the-trainers educational intervention. The physicians completed i) standardized forms on patient demographics, clinical course, and outcomes for patients seen in the treatment centers; ii) standardized surveys of feasibility and acceptability of use of CPAP/O2 helmet systems; and iii) in-depth-interviews to explore facilitators and barriers to implementation of CPAP/O2 helmet NIV. Physicians described the CPAP/O2 helmet ventilator as easy to use and they felt comfortable training their staff on its use. They rated CPAP/O2 helmet NIV as feasible, acceptable, and appropriate (mean score of 4.0, 3.8, and 3.9 out of 5, respectively, on standardized scales). Case report forms for 546 patients with suspected and/or confirmed COVID-19 infection were obtained between May 2020 and November 2021. Of these, 69% (n=376) were treated before the training; and 29.7% (n=162) were treated with CPAP/O2 helmet ventilation. CPAP/O2 helmet NIV was well-tolerated by patients, with 12% reporting claustrophobia, and 2% reporting loose- or tight-fitting helmets. Although patient outcomes improved among CPAP/O2 helmet users overall, this was not associated with training (P=0.2). This finding persisted after adjustment for disease severity at presentation. Serosurvey of 282 health workers across treatment centers revealed that 40% (n=112) were seropositive for SARS-CoV-2. Seropositivity was significantly associated with direct contact with COVID-19 patients and limited access to PPE and hand hygiene during aerosol generating procedures (P = 0.02), but not use of CPAP/O2 helmet (P’s ≥ 0.2). In conclusion, physicians effectively used CPAP/O2 helmet NIV systems to treat COVID-19 patients in Nigeria without need for practice facilliation of their training and without increased risk of infection among healthcare workers. The use of CPAP/O2 helmet NIV could be an important strategy for treating individuals with COVID-19 infection and other disease conditions complicated by respiratory distress, particularly in settings were resources such mechanical ventilation are limited.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04929691Clinical Protocols https://implementationsciencecomms.biomedcentral.com/articles/10.1186/s43058-021-00193-y https://acrobat.adobe.com/link/track?uri=urn:aaid:scds:US:1bff67f1-5fc3-3ed1-a68d-8dc3391abf6e Funding StatementThis study was funded by CDC Foundation award number 1085.1 and the Aliko Dangote Foundation grant number GS2008-0001Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the National Health Research Ethics Committee of Nigeria gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors